Document Detail

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
MedLine Citation:
PMID:  19142633     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We report the first clinicopathological series of longitudinal FDG-PET scans in post-mortem (PM) verified cognitively normal elderly (NL) followed to the onset of Alzheimer's-type dementia (DAT), and in patients with mild DAT with progressive cognitive deterioration.
METHODS: Four NL subjects and three patients with mild DAT received longitudinal clinical, neuropsychological and dynamic FDG-PET examinations with arterial input functions. NL subjects were followed for 13 +/- 5 years, received FDG-PET examinations over 7 +/- 2 years, and autopsy 6 +/- 3 years after the last FDG-PET. Two NL declined to mild cognitive impairment (MCI), and two developed probable DAT before death. DAT patients were followed for 9 +/- 3 years, received FDG-PET examinations over 3 +/- 2 years, and autopsy 7 +/- 1 years after the last FDG-PET. Two DAT patients progressed to moderate-to-severe dementia and one developed vascular dementia.
RESULTS: The two NL subjects who declined to DAT received a PM diagnosis of definite AD. Their FDG-PET scans indicated a progression of deficits in the cerebral metabolic rate for glucose (CMRglc) from the hippocampus to the parietotemporal and posterior cingulate cortices. One DAT patient showed AD with diffuse Lewy body disease (LBD) at PM, and her last in vivo PET was indicative of possible LBD for the presence of occipital as well as parietotemporal hypometabolism.
CONCLUSION: Progressive CMRglc reductions on FDG-PET occur years in advance of clinical DAT symptoms in patients with pathologically verified disease. The FDG-PET profiles in life were consistent with the PM diagnosis.
Lisa Mosconi; Rachel Mistur; Remigiusz Switalski; Wai Hon Tsui; Lidia Glodzik; Yi Li; Elizabeth Pirraglia; Susan De Santi; Barry Reisberg; Thomas Wisniewski; Mony J de Leon
Related Documents :
19729853 - Elevated levels of 4-hydroxynonenal-histidine michael adduct in the hippocampi of patie...
14746413 - Medical comorbidity in black and white patients with alzheimer's disease.
18270713 - Ct-guided lung biopsy: incidence of pneumothorax after instillation of nacl into the bi...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-01-14
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  36     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-10     Completed Date:  2009-08-11     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  811-22     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alzheimer Disease / diagnosis*,  radionuclide imaging*
Brain / metabolism*
Cognition Disorders / diagnosis,  radionuclide imaging
Dementia, Vascular / diagnosis,  radionuclide imaging
Fluorodeoxyglucose F18 / pharmacology*
Glucose / metabolism*
Hippocampus / metabolism
Lewy Body Disease / metabolism
Positron-Emission Tomography / methods*
Grant Support
AG022374/AG/NIA NIH HHS; AG03051/AG/NIA NIH HHS; AG08051/AG/NIA NIH HHS; AG12101/AG/NIA NIH HHS; AG13616/AG/NIA NIH HHS; M01 RR000096-47/RR/NCRR NIH HHS; M01RR0096/RR/NCRR NIH HHS; P30 AG008051/AG/NIA NIH HHS; P30 AG008051-199005/AG/NIA NIH HHS; R01 AG012101/AG/NIA NIH HHS; R01 AG012101-15/AG/NIA NIH HHS; R01 AG013616/AG/NIA NIH HHS; R01 AG013616-17/AG/NIA NIH HHS; R01 AG022374/AG/NIA NIH HHS; R01 AG022374-05/AG/NIA NIH HHS
Reg. No./Substance:
0Z5B2CJX4D/Fluorodeoxyglucose F18; IY9XDZ35W2/Glucose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Metal artifact reduction image reconstruction algorithm for CT of implanted metal orthopedic devices...
Next Document:  [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis t...